Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets

Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations, it added. The group now has 327 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news